NDAORALTABLET
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Clinical Trials (1)
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Started Feb 2013
607 enrolled
Diabetes Mellitus, Type 2
Loss of Exclusivity
LOE Date
Dec 8, 2037
143 months away
Patent Expiry
Dec 8, 2037
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8883805 | Nov 26, 2025Expired | Product | — |
| 8883805*PED | May 26, 2026 | — | |
| 7713938 | Apr 15, 2027 | SubstanceProduct | — |
| 12178819 | May 4, 2027 | Product | — |
| 9173859 | May 4, 2027 | Product | U-1772 |